Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiotherapy in Melanoma
NCT02562625Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Aug 2016
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Induction of an Abscopal Effect at 12 weeks. Started Aug 2016; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02562625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562625.